Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ArriVent BioPharma, Inc.AVBP · Entity 4699 | Director | June 18, 2026 | June 23, 2026 |
| Jasper Therapeutics, Inc.JSPR · Entity 7588 | Director | July 03, 2025 | July 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ArriVent BioPharma, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.74 · Expires 2036-06-17 | Direct | 13,562 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 13,562 · Balance 13,562 F1: The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date.
Jasper Therapeutics, Inc.
Report date July 03, 2025 · Filed July 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.77 · Expires 2035-07-03 | Direct | 7,500 |
Reported balance
After 2025-07-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-03 · Grant · Acquired 7,500 · Balance 7,500 F1: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
POLARITYTE, INC.
Report date January 12, 2023 · Filed January 17, 2023
Section 16 reporting ended · disclosed 2023-01-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,403 |
Reported balance
After 2023-01-12 transaction · row 1
1 source rowRow 1 · 2023-01-12 · Exercise / conversion · Disposed 36,497 · Balance 14,403 F1: Pursuant to the issuer's non-executive director compensation plan the reporting person was issued 50,900 Restricted Stock Units vesting in equal installments quarterly in arrears, which were previously reported on Form 4 under Table I. As of the date of the reporting person's end of service as a director on January 12, 2023, 36,497 restricted stock units that had not vested as of that date were forfeited. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.50 · Expires 2030-04-06 | Direct | 6,157 |
Reported balance
After 2023-01-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-12 · Exercise / conversion · Disposed 3,078 · Balance 6,157 F2: The stock option was granted 04/06/2020, and reported under Table II of Form 4. The number of derivative securities and price have been adjusted to give effect to a 25-to-1 reverse stock split in May 2022. As of the date of the reporting person's end of service as a director on January 12, 2023, 3,078 stock options that had not vested as of that date were forfeited. The remaining 6,157 stock options were fully vested as of 04/06/2022, and are presently exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the issuer's non-executive director compensation plan the reporting person was issued 50,900 Restricted Stock Units vesting in equal installments quarterly in arrears, which were previously reported on Form 4 under Table I. As of the date of the reporting person's end of service as a director on January 12, 2023, 36,497 restricted stock units that had not vested as of that date were forfeited.
F2: The stock option was granted 04/06/2020, and reported under Table II of Form 4. The number of derivative securities and price have been adjusted to give effect to a 25-to-1 reverse stock split in May 2022. As of the date of the reporting person's end of service as a director on January 12, 2023, 3,078 stock options that had not vested as of that date were forfeited. The remaining 6,157 stock options were fully vested as of 04/06/2022, and are presently exercisable.
Revance Therapeutics, Inc.
Report date February 04, 2025 · Filed February 06, 2025
Section 16 reporting ended · disclosed 2025-02-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-02-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-04 · Other · Disposed 28,606 · Balance 15,000 F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Row 2 · 2025-02-06 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer.
F2: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price.
Viela Bio, Inc.
Report date March 15, 2021 · Filed March 15, 2021
Section 16 reporting ended · disclosed 2021-03-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.00 · Expires 2029-10-01 | Direct | 0 |
Reported balance
After 2021-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-15 · Disposition to issuer · Disposed 26,210 · Balance 0 F1: Reflects disposition of options to purchase Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the "Merger Agreement"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. ("Purchaser"), and for certain purposes, Horizon Therapeutics plc, including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. F2: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.96 · Expires 2030-06-18 | Direct | 0 |
Reported balance
After 2021-03-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-15 · Disposition to issuer · Disposed 7,358 · Balance 0 F1: Reflects disposition of options to purchase Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the "Merger Agreement"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. ("Purchaser"), and for certain purposes, Horizon Therapeutics plc, including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. F2: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of options to purchase Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the "Merger Agreement"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. ("Purchaser"), and for certain purposes, Horizon Therapeutics plc, including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
F2: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 23, 2026 01:46 UTC | ArriVent BioPharma, Inc. AVBP · Entity 4699 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,562 | $0.00 Strike: $31.74 | $0.00 |
DisclosureSEC source: 0001104659-26-076566 · tm2618519-1_4seq1.xml · derivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,562 Underlying: Common Stock · 13,562 shares Expires 2036-06-17 F1 · derivative.exercise_date: The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| July 03, 2025 Filed Jul 3, 2025 20:23 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $6.77 | $0.00 |
DisclosureSEC source: 0001213900-25-061498 · ownership.xml · derivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Voting Common Stock · 7,500 shares Expires 2035-07-03 F1 · shares: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 23:29 UTC | ArriVent BioPharma, Inc. AVBP · Entity 4699 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,502 | $0.00 Strike: $24.89 | $0.00 |
DisclosureSEC source: 0001104659-25-061267 · tm2518583-1_4seq1.xml · derivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,502 Underlying: Common Stock · 15,502 shares Expires 2035-06-17 Read SEC document |
| February 06, 2025 Filed Feb 6, 2025 15:48 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Disposition to issuerCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-015339 · ownership.xml · nonDerivative · entry 2 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 15:48 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | OtherCommon Stock | 28,606 | $3.65 | $104,411.90 |
DisclosureSEC source: 0000950170-25-015339 · ownership.xml · nonDerivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · kind: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 22:28 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $25.41 | $0.00 |
DisclosureSEC source: 0001213900-24-051414 · ownership.xml · derivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Voting Common Stock · 7,500 shares Expires 2034-06-06 Read SEC document |
| May 01, 2024 Filed May 3, 2024 08:46 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 23,458 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001479290-24-000088 · wk-form4_1714740373.xml · derivative · entry 2 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,458 Underlying: Common Stock · 23,458 shares Expires 2034-04-30 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 01, 2024 Filed May 3, 2024 08:46 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-24-000088 · wk-form4_1714740373.xml · nonDerivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,606 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 21:16 UTC | ArriVent BioPharma, Inc. AVBP · Entity 4699 | GrantStock Option (right to buy) · Derivative | 17,884 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001104659-24-007733 · tm244377-2_4seq1.xml · derivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,884 Underlying: Common Stock · 17,884 shares Expires 2034-01-24 F1 · derivative.exercise_date: These options vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 22:42 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 47,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001213900-23-047569 · ownership.xml · derivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 Underlying: Voting Common Stock · 47,000 shares Expires 2033-06-07 Read SEC document |
| May 03, 2023 Filed May 5, 2023 17:14 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 5,915 | $0.00 Strike: $33.61 | $0.00 |
DisclosureSEC source: 0001479290-23-000062 · wf-form4_168332128227955.xml · derivative · entry 2 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,915 Underlying: Common Stock · 5,915 shares Expires 2033-05-02 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 3, 2024 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to Mr. Nolet's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 03, 2023 Filed May 5, 2023 17:14 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 3,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-23-000062 · wf-form4_168332128227955.xml · nonDerivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,606 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 3, 2024 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to Mr. Nolet's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| January 12, 2023 Filed Jan 17, 2023 16:30 UTC | POLARITYTE, INC. PTE · Entity 117561 | Exercise / conversionStock option (right to buy) · Derivative | 3,078 | $0.00 Strike: $22.50 | $0.00 |
DisclosureSEC source: 0001493152-23-001628 · ownership.xml · derivative · entry 2 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,157 Underlying: Common Stock · 9,235 shares Expires 2030-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The stock option was granted 04/06/2020, and reported under Table II of Form 4. The number of derivative securities and price have been adjusted to give effect to a 25-to-1 reverse stock split in May 2022. As of the date of the reporting person's end of service as a director on January 12, 2023, 3,078 stock options that had not vested as of that date were forfeited. The remaining 6,157 stock options were fully vested as of 04/06/2022, and are presently exercisable. F2 · derivative.exercise_date: The stock option was granted 04/06/2020, and reported under Table II of Form 4. The number of derivative securities and price have been adjusted to give effect to a 25-to-1 reverse stock split in May 2022. As of the date of the reporting person's end of service as a director on January 12, 2023, 3,078 stock options that had not vested as of that date were forfeited. The remaining 6,157 stock options were fully vested as of 04/06/2022, and are presently exercisable. Read SEC document |
| January 12, 2023 Filed Jan 17, 2023 16:30 UTC | POLARITYTE, INC. PTE · Entity 117561 | Exercise / conversionCommon Stock | 36,497 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-001628 · ownership.xml · nonDerivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Pursuant to the issuer's non-executive director compensation plan the reporting person was issued 50,900 Restricted Stock Units vesting in equal installments quarterly in arrears, which were previously reported on Form 4 under Table I. As of the date of the reporting person's end of service as a director on January 12, 2023, 36,497 restricted stock units that had not vested as of that date were forfeited. Read SEC document |
| October 12, 2022 Filed Oct 14, 2022 00:00 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantVoting Common Stock | 32,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-063938 · ownership.xml · nonDerivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 F1 · shares: The reported securities are represented by restricted stock units, 1/2 of which shall vest on each of April 12, 2023 and October 12, 2023, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| October 01, 2022 Filed Oct 4, 2022 17:00 UTC | POLARITYTE, INC. PTE · Entity 117561 | GrantCommon Stock | 50,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-027578 · ownership.xml · nonDerivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,900 F1 · shares: Pursuant to the issuer's non-executive director compensation plan the reporting person was issued 50,900 Restricted Stock Units vesting in equal installments quarterly in arrears. Read SEC document |
| May 04, 2022 Filed May 6, 2022 18:19 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 11,343 | $0.00 Strike: $18.12 | $0.00 |
DisclosureSEC source: 0001479290-22-000063 · wf-form4_165187555569277.xml · derivative · entry 2 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,343 Underlying: Common Stock · 11,343 shares Expires 2032-05-03 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Mr. Nolet's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 04, 2022 Filed May 6, 2022 18:19 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 6,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-22-000063 · wf-form4_165187555569277.xml · nonDerivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,072 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 4, 2023, subject to Mr. Nolet's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| May 04, 2022 Filed May 13, 2022 18:11 UTC Amendment | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 10,756 | $0.00 Strike: $18.12 | $0.00 |
DisclosureSEC source: 0001479290-22-000067 · wf-form4a_165247985603673.xml · derivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,756 Underlying: Common Stock · 10,756 shares Expires 2032-05-03 F1 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Mr. Nolet's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) through such vesting date. The stock option represents an annual grant pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 22:01 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 78,045 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001213900-22-014564 · ownership.xml · derivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,045 Underlying: Voting Common Stock · 78,045 shares Expires 2032-03-21 F1 · derivative.exercise_date: 1/3rd of the shares subject to the option shall vest on December 7, 2022, and 1/3rd of the shares subject to the option shall vest on each anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| May 05, 2021 Filed May 7, 2021 19:10 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 7,551 | $0.00 Strike: $27.91 | $0.00 |
DisclosureSEC source: 0001479290-21-000112 · wf-form4_162042902149962.xml · derivative · entry 2 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,551 Underlying: Common Stock · 7,551 shares Expires 2031-05-04 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 5, 2022, subject to Mr. Nolet's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 05, 2021 Filed May 7, 2021 19:10 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 4,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-21-000112 · wf-form4_162042902149962.xml · nonDerivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,013 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 5, 2022, subject to Mr. Nolet's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| March 15, 2021 Filed Mar 15, 2021 09:15 UTC | Viela Bio, Inc. VIE · Entity 141253 | Disposition to issuerStock Option (right to buy) · Derivative | 7,358 | Not disclosed Strike: $48.96 | Not disclosed |
DisclosureSEC source: 0000899243-21-011497 · doc4.xml · derivative · entry 2 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,358 shares Expires 2030-06-18 F1 · kind: Reflects disposition of options to purchase Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the "Merger Agreement"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. ("Purchaser"), and for certain purposes, Horizon Therapeutics plc, including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. Read SEC document |
| March 15, 2021 Filed Mar 15, 2021 09:15 UTC | Viela Bio, Inc. VIE · Entity 141253 | Disposition to issuerStock Option (right to buy) · Derivative | 26,210 | Not disclosed Strike: $19.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-011497 · doc4.xml · derivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,210 shares Expires 2029-10-01 F1 · kind: Reflects disposition of options to purchase Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the "Merger Agreement"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. ("Purchaser"), and for certain purposes, Horizon Therapeutics plc, including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 16:10 UTC | POLARITYTE, INC. PTE · Entity 117561 | GrantStock option (Right to Buy) · Derivative | 166,443 | $0.48 Strike: $0.68 | $79,892.64 |
DisclosureSEC source: 0001493152-21-000207 · ownership.xml · derivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,443 Underlying: Common Stock · 166,443 shares Expires 2031-01-01 F1 · price: On January 1, 2021, the reporting person was issued a common stock option under the issuer's 2017 Equity Incentive Plan for 166,443 shares vesting in 12 monthly installments beginning February 1, 2021 with a fair value of $0.48 per option share as annual compensation awarded under the issuer's non-executive director compensation plan. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 16:44 UTC | Viela Bio, Inc. VIE · Entity 141253 | GrantStock Option (right to buy) · Derivative | 7,358 | $0.00 Strike: $48.96 | $0.00 |
DisclosureSEC source: 0001209191-20-038491 · doc4.xml · derivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,358 Underlying: Common Stock · 7,358 shares Expires 2030-06-18 F1 · derivative.exercise_date: These options vest on the first anniversary date of the grant. Read SEC document |
| May 14, 2020 Filed May 15, 2020 18:41 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 12,000 | $0.00 Strike: $19.40 | $0.00 |
DisclosureSEC source: 0001479290-20-000068 · wf-form4_158958247346516.xml · derivative · entry 2 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-05-13 F2 · derivative.exercise_date: The shares subject to the stock option shall vest May 14, 2021, the one year anniversary from the grant date, subject to Mr. Nolet's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 14, 2020 Filed May 15, 2020 18:41 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-20-000068 · wf-form4_158958247346516.xml · nonDerivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Mr. Nolet's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| April 06, 2020 Filed Apr 7, 2020 16:30 UTC | POLARITYTE, INC. PTE · Entity 117561 | GrantStock Option (right to buy) · Derivative | 230,894 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001493152-20-005993 · ownership.xml · derivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,894 Underlying: Common Stock · 230,894 shares Expires 2030-04-06 F1 · derivative.exercise_date: These options vest over a three-year period with one third vesting on each anniversary of the grant date. Read SEC document |
| October 02, 2019 Filed Oct 2, 2019 21:51 UTC | Viela Bio, Inc. VIE · Entity 141253 | GrantStock Option (right to buy) · Derivative | 26,210 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-19-024843 · doc4.xml · derivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,210 Underlying: Common Stock · 26,210 shares Expires 2029-10-01 F1 · derivative.exercise_date: These options vest over a three-year period with one third vesting on each anniversary of the grant date. Read SEC document |
| July 16, 2019 Filed Jul 18, 2019 20:29 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 18,000 | $0.00 Strike: $12.32 | $0.00 |
DisclosureSEC source: 0001479290-19-000083 · wf-form4_156349614702794.xml · derivative · entry 2 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2029-07-15 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on July 16, 2020, the one year anniversary of the grant date, subject to Mr. Nolet's Continuous Service (as defined in the Plan) through such vesting date. Read SEC document |
| July 16, 2019 Filed Jul 18, 2019 20:29 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-19-000083 · wf-form4_156349614702794.xml · nonDerivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · shares: Represents an initial restricted stock award (the "RSA"). The shares underlying the RSA shall vest on July 16, 2020, the one year anniversary from the grant date, subject to Mr. Nolet's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.